Patents by Inventor Roland Martin

Roland Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10873027
    Abstract: A process for the manufacture of a multilayer structure suitable for forming part of an organic electronic device having a cathode and an anode wherein liquid compositions with solvent systems comprising organic compounds with ionizable groups are deposited out of solution. Organic electronic devices can be made with use of the process including transistors, diodes, and photovoltaic devices, including organic light emitting diodes (OLEDs).
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: December 22, 2020
    Assignee: Nissan Chemical Industries, Ltd.
    Inventor: Roland Martin
  • Publication number: 20200071390
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 5, 2020
    Inventors: Jan GRIMM, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Patent number: 10450365
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: October 22, 2019
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Publication number: 20190002575
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
    Type: Application
    Filed: September 17, 2018
    Publication date: January 3, 2019
    Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
  • Publication number: 20180237532
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Roland MARTIN, Henry MCFARLAND, Bibiana BIELEKOVA
  • Publication number: 20180037635
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Application
    Filed: August 16, 2017
    Publication date: February 8, 2018
    Inventors: Jan GRIMM, Roland MARTIN, Benoit COMBALUZIER, Ivan JELCIC
  • Patent number: 9771413
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: September 26, 2017
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Patent number: 9738690
    Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: August 22, 2017
    Assignee: UNIVERSITAET ZUERICH
    Inventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
  • Publication number: 20170190779
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
    Type: Application
    Filed: August 11, 2016
    Publication date: July 6, 2017
    Inventors: Roland MARTIN, Henry McFarland, Bibiana Bielekova
  • Publication number: 20160052996
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Application
    Filed: January 2, 2014
    Publication date: February 25, 2016
    Inventors: Jan GRIMM, Roland MARTIN, Benoit COMBALUZIER, Ivan JELCIC
  • Patent number: 9260692
    Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: February 16, 2016
    Assignee: UNIVERSITAT ZURICH
    Inventors: Roland Martin, Andreas Lutterotti
  • Publication number: 20150337044
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
    Type: Application
    Filed: July 6, 2015
    Publication date: November 26, 2015
    Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
  • Publication number: 20150157651
    Abstract: The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and/or secondary progressive multiple sclerosis (SP-MS). The tri-substituted glycerol compounds according to formula (I) as described herein may also be used for the treatment of multiple sclerosis patients not adequately responding to interferon therapy. The present invention also relates to a tri-substituted glycerol compound as described herein, for use as a medicament, wherein the tri-substituted glycerol compound is administered in combination with at least one further pharmaceutically active compound.
    Type: Application
    Filed: May 21, 2013
    Publication date: June 11, 2015
    Inventors: Pierre Abramowski, Roland Martin
  • Publication number: 20150010477
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 8, 2015
    Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
  • Publication number: 20140356320
    Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
    Type: Application
    Filed: July 23, 2012
    Publication date: December 4, 2014
    Applicant: Universit├Ąt Z├╝rich
    Inventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
  • Publication number: 20140212445
    Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 31, 2014
    Applicant: UNIVERSITAT ZURICH
    Inventors: Roland MARTIN, Andreas LUTTEROTTI
  • Publication number: 20140159013
    Abstract: A process for the manufacture of a multilayer structure suitable for forming part of an organic electronic device having a cathode and an anode wherein liquid compositions with solvent systems comprising organic compounds with ionizable groups are deposited out of solution.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 12, 2014
    Applicant: SOLVAY SA
    Inventor: Roland MARTIN
  • Patent number: 8673293
    Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: March 18, 2014
    Assignee: Universitat Zurich
    Inventors: Roland Martin, Andreas Lutterotti, Stephen Miller
  • Patent number: 8636997
    Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 28, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann
  • Patent number: 8586973
    Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: November 19, 2013
    Assignee: Solvay SA
    Inventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur, Jonathan Maunoury